InvestorsHub Logo
Followers 0
Posts 97
Boards Moderated 0
Alias Born 09/28/2016

Re: Jumpinjackas post# 1275

Thursday, 09/21/2017 8:44:20 AM

Thursday, September 21, 2017 8:44:20 AM

Post# of 2099
Agree, with both, very unlikely they are not truly blinded.

As a fellow data analyst, Jumpin is right. If someone outside is not managing the trial, then they have access to all the data. Data analysts for trials continually received enough subject demographic, subject visit, and laboratory/clinical measures to piece together what is going on.

Honestly, enrollment dates by arm, and number of events reach per arm really could be enough to have a solid estimate with a few assumptions. If the data are managed in-house, then you could increase confidence by comparing the distributions of response measures (ie. tumor shrinkage) between the Ph3 data and Ph2 results (Slide 19 of Sept17 deck).
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VBLT News